News Category
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the p...
VERAXA Biotech AG appoints Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor therapies, signaling a strategic push towa...
NanoViricides announced a $3.8 million registered direct offering to a single institutional investor, providing capital to advance its broad-spectrum ...
VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer, effective immediately, to lead the ...
VERAXA Biotech has obtained Scientific Advice from Germany's Paul-Ehrlich-Institute supporting the development strategy for its lead BiTAC(R)-TCE prog...
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute, clarifying its development strategy for the BiTAC-TCE platform, wi...
Siegfried appoints Eduardo Montanha as COO to lead combined Drug Substances and Drug Products operations, enhancing end-to-end solutions and global su...
NextPlat Corp's planned acquisition of an independent pharmacy in rural Florida for $1.5 million aims to expand its PharmcoRx footprint into an unders...
Onco-Innovations Limited announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key...
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program in partnership with ATUM, marking a key milestone toward ...
The global sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036, driven by chronic disease p...
VERAXA Biotech provided a corporate update detailing advancements in its BiTAC platform, including four T-cell engager programs and plans to monetize ...
VERAXA Biotech has begun cell line development for its BiTAC T-cell engager program, leveraging ATUM's Leap-In Transposase technology to advance a nov...
The article discusses how VERAXA Biotech AG's antibody engineering platform aligns with strong deal activity in ADCs and T-cell engagers, similar to t...
Ace Therapeutics announces end-to-end preclinical analgesic drug development services featuring validated in vivo and in vitro pain models, target-bas...
Medios AG is closing its Aschaffenburg facility and consolidating production at other sites to improve profitability, reflecting the ongoing margin pr...
Helus Pharma announced fiscal 2026 financial results, highlighting that its Phase 3 APPROACH trial for HLP003 in major depressive disorder has surpass...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction plant and an integrated contrast drug man...
Knight Therapeutics repaid its $60 million revolving credit facility used to fund the Paladin acquisition, demonstrating strong operational cash flow ...
Voyageur Pharmaceuticals is assessing potential locations in Oklahoma and Texas for a vertically integrated contrast media plant, aiming to reduce cos...
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals has submitted a multi-year exploration permit application for its Frances Creek barite project, aiming to advance a feasibili...
Voyageur Pharmaceuticals raised C$5,005,278 through a non-brokered private placement to fund FDA licensing for its barium contrast products, regulator...
Kairos Pharma Ltd. plans to acquire worldwide rights to a Phase 1-ready oral c-MET kinase inhibitor, expanding its oncology pipeline and advancing cli...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, while its commercial product ...
Quantum BioPharma Ltd. progresses its differentiated multiple sclerosis therapy Lucid-MS into Phase 2 planning, supported by strong financial runway a...
Redwood AI Corp. announced DTC eligibility for its common shares to simplify U.S. trading and enhance liquidity, along with engaging InvestorBrandNetw...
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is featured in a CityBiz Q&A with founder Mu...
Sino Biological's new cell-free protein synthesis kit enables ultra-fast antibody production in 3 hours, integrating with AI-driven high-throughput sc...
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
NanoViricides has priced a $2 million registered direct offering with an institutional investor, providing capital to advance its broad-spectrum antiv...
Lantern Pharma's $4.4 million registered direct offering, with potential additional proceeds from warrants, underscores investor confidence in its AI-...
Tonix Pharmaceuticals announced its participation in two upcoming investor conferences, highlighting its commercial progress and pipeline developments...
Lantern Pharma's expansion of its predictBBB platform into a Large Quantitative Model offers researchers a real-time web-based tool for generating com...
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and immunotherapy by disrupting DNA repai...
Soligenix is leveraging its synthetic hypericin platform to target multiple skin conditions, demonstrating a cost-effective approach to drug developme...
At PolyPeptide's fifth AGM, shareholders approved all board proposals, including re-election of directors and auditors, compensation, and financial re...
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, detailing a transformative year with leadership changes, clinical progress, the ...
LIXTE Biotechnology's lead compound LB-100, the first and only clinical-stage inhibitor of protein phosphatase 2A, shows promise in enhancing cancer t...
Lonza nominates Stephen Fry, a former Eli Lilly executive with deep pharma experience, as an independent board member to strengthen governance and per...
Voyageur Pharmaceuticals is progressing its barium and iodine contrast media projects with bankable feasibility studies, FDA submissions, and strategi...
Soligenix receives positive opinion from EMA’s Committee for Orphan Medicinal Products for dusquetide in Behçet’s disease, unlocking development incen...
Quoin Pharmaceuticals' NETHERTON NOW campaign has garnered nearly 2 million video views and 24 million impressions, amplifying awareness of Netherton ...
Oncotelic Therapeutics was highlighted in a BioMedWire editorial discussing the increasing M&A focus on de-risked, late-stage biotech assets, aligning...
Helus Pharma announced that its Phase 2a trial data for SPL026, published in Nature Medicine, demonstrated statistically significant and clinically me...
BioVaxys announced positive Phase 2 results for its immunotherapy MVP-S combined with pembrolizumab and low-dose cyclophosphamide in metastatic bladde...
Quantumzyme Corp. reports 2025 advances in enzyme R&D and AI integration, plans name change to Quantum Genesis AI Corp., and sets 2026 priorities incl...
Creative Biolabs announces a strategic upgrade to its biosimilar development and CDMO platform, enhancing physicochemical characterization and biologi...
